** Shares of some weight-loss drug developers rise premarket, after Novo Nordisk's NOVOb.CO experimental next-generation obesity drug achieves lower weight loss than expected in a late-stage trial
** Novo says its drug, CagriSema, helped overweight patients cut their weight by 22.7%, below the 25% it had expected
** Shares of Viking Therapeutics VKTX.O up 11.5%, Structure Therapeutics GPCR.O up 7.1%, Altimmune ALT.O up 2.2% and Amgen AMGN.O climb 5.5% before the bell
** U.S.-listed shares of Novo fall 22.4%, while rival Eli Lilly LLY.N climbs 10%
** Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market
** Lilly's obesity drug, sold as Zepbound in the U.S., led to an average weight loss of nearly 23% in clinical trials
** Up to last close, AMGN down 9.3%, GPCR down 26.5% and ALT down 27.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。